---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-008683"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T08:49:47.704762+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kala Pharma Q1 net loss $14.5M; KPI-012 CHASE Phase 2b enrolling with topline data Q1 2024

## Summary
- Q1 2023 net loss $14.5M ($6.99/share) vs $32.9M ($22.18/share) in Q1 2022; no product revenue post-Alcon sale.
- Cash and equivalents $63.6M at March 31, 2023; plus $15M CIRM grant awarded April 2023 extends runway into Q1 2025.
- KPI-012 for PCED received FDA Fast Track designation; CHASE Phase 2b primary enrollment ongoing; topline data targeted Q1 2024.
- Appointed Dr. Francis Mah as Chief Medical Advisor in March 2023 to support clinical development.

## SEC filing metadata
- accession: 0001558370-23-008683
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837023008683/0001558370-23-008683-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837023008683/kala-20230509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-008683
- JSON: https://secwatch.observer/filing/0001558370-23-008683.json
- Plain text: https://secwatch.observer/filing/0001558370-23-008683.txt

## Key facts
- Earnings Releases
  KALA BIO, Inc. reported financial results for the quarter ended March 31, 2023.
  - Period: the quarter ended March 31, 2023
  - Result: reported results
  source text: On May 9, 2023, Kala Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2023 and provided a general business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837023008683/0001558370-23-008683-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.